Community/Retail

Jennifer Goldman, PharmD, highlights clinical trial data and practical strategies for pharmacists to support initiation, adherence, and adverse effect management with tirzepatide at the American Pharmacists Association Annual Meeting and Exposition.

Researchers shed new light on how zinc deficiency contributes to severe disease and death, pointing to a specific intracellular protein as a key mediator.

Waters Corporation's Onclarity HPV Self-Collection Kit represents a significant advance in expanding access to cervical cancer screening outside the clinic.

Pharmacists play a critical and evolving role in sports medicine by optimizing medication use, guiding safe supplementation, and delivering personalized, prevention-focused care to support athlete performance and overall health.

Independent pharmacies are being squeezed on reimbursement while their data quietly fuels billion-dollar decisions. A new pharmacy data economy could flip that script.

The CDC testing pause disrupts diagnostic testing for infectious diseases like rabies and mpox, leaving pharmacists and states scrambling for answers.

Keith Bellovich, DO, explains how SARS-CoV-2–driven inflammation contributes to kidney injury and may reveal previously undiagnosed chronic kidney disease.

Practical strategies to improve clozapine education, monitoring, and utilization while addressing common barriers and safety concerns.

Pharmacists play a central role in implementing new dyslipidemia guidelines, including ApoB testing, earlier risk assessment, and expanded use of combination lipid-lowering therapy.

The influenza vaccine halves the risk of heart attack and stroke after infection, offering cardiovascular protection even when breakthrough influenza occurs.

Erin Dorval, PharmD, highlights the pharmacist’s role in safe athlete pain management, emphasizing appropriate NSAID use, alternative therapies, and emerging trends such as personalized care and wearable-driven performance optimization.

AI is reshaping pharmacy, from catching dangerous drug interactions to personalizing chemotherapy dosing.

New analysis suggests oral semaglutide may offer improved efficacy and tolerability compared with orforglipron, informing treatment selection in an increasingly competitive oral GLP-1 landscape.

Review finds prior authorizations delay neurologic treatment, trigger relapses, and intensify clinician burnout, spurring calls for rapid reform.

Ahead of the Sports Pharmacy Summit, Erin Dorval, PharmD, highlights the pharmacist’s role in optimizing athlete performance and recovery through safe medication use, careful supplement evaluation, and a holistic, risk-minimizing approach to care.

The first-in-class triple agonist met all primary and key secondary end points in the TRANSCEND-T2D-1 trial.

The National Association of Boards of Pharmacy (NABP) opens the door to the Occupational English Test (OET) as an alternative English exam for foreign pharmacy graduate certification.

Data from a new 20-year analysis reveal persistent inequities in influenza vaccination among a high-risk cardiovascular population.

Pharmacy supply chain disruptions directly shape the treatment that patients receive, making it vital that pharmacists understand the causes and consequences of delays.

Brandon Welch, PharmD, highlights the expanding role of sports pharmacists in medication safety, anti-doping, and personalized athlete care.

Joseph Saseen, PharmD, addresses statin intolerance and misinformation and provides a look at aggressive new LDL targets and emerging therapies not yet captured in the 2026 guidelines.

Pulse by NABP is revolutionizing drug supply chain oversight and patient safety.

AHA Epidemiology Sessions 2026 show that chronic kidney disease (CKD) proteinuria drops of 30% or more cut heart failure, major adverse cardiovascular events, and death, a key prevention signal.

As pharmacy technology consolidates under a few powerful platforms, independent pharmacies risk losing control of the data—and leverage—they generate every day.

Deucravacitinib offers a targeted, well-tolerated oral option for patients with psoriatic arthritis, with efficacy comparable to biologics and meaningful benefits in patient-reported outcomes.

The approval is supported by clinical data from the ATTAIN-1 and ATTAIN-2 trials.

The updated dosing schedule for nusinersen offers increased drug exposure and may further improve outcomes for patients with spinal muscular atrophy.

There was limited evidence supporting additional clinical benefits.